04
Mar
2010
Posted in I - Series B, Q - 1Q10, R - INTERNATIONAL, X - Antibody, X - Inflammation, X - Oncology
Merus (Netherlands) a preclinical-stage biopharmaceutical focused on antibody product candidates against targets in oncology, inflammation and infectious disease, closed a $30.7M Series B financing. Participants include Novartis Option Fund, Pfizer, Bay City Capital, Life Sciences Partners and Aglaia Biomedical Ventures.
01
Mar
2010
Posted in I - Series A, Q - 1Q10, R - INTERNATIONAL, X - Antibody, X - Therapeutic Platform
F-star Biotech (Austria) a development-stage based biopharma company focused upon an antibody design platform, with product and indication(s) to be identified, closed a $10.8M Series A financing, bringing the total round to $25.8M. Participants include MP Healthcare Venture Management, Merck Serono Ventures, Atlas Venture, Aescap Venture, Novo Ventures and TVM Capital.
22
Feb
2010
11
Feb
2010
Posted in I - Series A, Q - 4Q09, R - INTERNATIONAL, X - Antibody, X - Autoimmune, X - Oncology, X - Therapeutic Platform
arGEN-X (Netherlands) a development-stage biopharmaceutical company focused on a monoclonal antibody platform with potential indications in autoimmunity, oncology and bone disease, closed a $4.5M Series A financing, bring total round proceeds to $18.3M. Participants have included Credit Agricole Private Equity, Forbion Capital Partners, Life Science Partners, KBC Private Equity, BioGeneration Ventures, Erasmus MC Biomedical Fund, [...]
11
Feb
2010
11
Feb
2010
10
Feb
2010
09
Feb
2010
Posted in I - Series C, Q - 4Q09, R - INTERNATIONAL, X - Allergy, X - Immunology, X - Vaccines
Circassia (United Kingdom) a clinical-stage specialty biopharmaceutical focused on therapeutic T-cell vaccines for allergies and organ transplant rejection, closed a $25M Series C financing. Participants include Imperial Innovations, Invesco Perpetual and Lansdowne Partners.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb
05
Feb
2010
Posted in I - Series B, Q - 4Q09, R - INTERNATIONAL, X - Cardiology, X - Renal, X - Synthetic Biology
Evolva (Switzerland) a clinical-stage synthetic biology small molecule company focused on proteinuri kidney and cardiovascular disease, closed a $15.2M Series B financing bringing the total round up to $42.3M. Participants include Wellington Partners, Aravis Venture Associates, Auriga Partners and Vinci Capital.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb
04
Feb
2010
Posted in I - Series B, Q - 4Q09, R - INTERNATIONAL, X - DARPin, X - Opthalmology, X - Therapeutic Platform
Molecular Partners (Switzerland) a preclinical-stage developing DARPins, a potential new class of protein therapeutics focused on ophthalmology indications, closed a $45M Series B financing. Participants include Essex Woodlands Health Ventures, Index Ventures, Johnson & Johnson Development Corp., BB Biotech Ventures and EndeavourVision.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb